Target intelligence / Profile preview

Double homeobox 4 (DUX4) messenger RNA (DUX4 mRNA)

Target
DUX4 mRNA
Molecular classification
Messenger RNA, RNA, Other
01

Overview

Double homeobox 4 (DUX4) messenger RNA (mRNA) is the transcript of the DUX4 gene, which encodes a transcription factor that is normally expressed only during early embryonic development and is epigenetically silenced in adult somatic tissues. In patients with facioscapulohumeral muscular dystrophy (FSHD), genetic mutations lead to the failure of epigenetic suppression, resulting in the aberrant, toxic expression of DUX4 mRNA and protein in skeletal muscle. This ectopic expression triggers a cascade of downstream transcriptional changes that cause muscle fiber degeneration, oxidative stress, inflammation, and apoptosis.\n\nConsequently, DUX4 mRNA has emerged as a primary therapeutic target for disease-modifying treatments. Therapeutic strategies focus on sequence-specific knockdown of the transcript using RNA interference (RNAi) or antisense oligonucleotides (ASOs) to prevent the translation of the toxic DUX4 protein. Promising clinical-stage candidates, such as delpacibart braxlosiran (del-brax) and DYNE-302, utilize antibody-oligonucleotide conjugates (AOCs) targeting transferrin receptor 1 (TfR1) to deliver DUX4-specific small interfering RNAs (siRNAs) directly into skeletal muscle cells. These therapies aim to halt or reverse muscle wasting and improve functional mobility in patients with FSHD.

Other names
DUX4 RNADUX4 transcriptDUX4 messenger RNADouble homeobox 4 transcriptDouble homeobox 4 mRNADouble homeobox protein 4 transcriptDouble homeobox protein 4 mRNA
02

Mechanism of action

RNA interference (RNAi) or antisense knockdown leading to sequence-specific degradation of DUX4 mRNA, thereby preventing translation of the toxic DUX4 protein.

03

Biological functions

Transcription regulationApoptosisCell deathMyogenesisOther
04

Disease associations

Facioscapulohumeral muscular dystrophyFacioscapulohumeral muscular dystrophy type 1Facioscapulohumeral muscular dystrophy type 2Other
05

Safety considerations

Delivery to skeletal muscleOff-target effects of siRNA/oligonucleotidesPotential for immune response to the delivery vehicleAnemia and reticulocyte depletion associated with TfR1-targeting antibodiesTfR1 depletion
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

KHDC1L proteinCreatine kinaseDUX4-regulated gene expressionQuantitative Muscle Testing (QMT) scoreMuscle MRI

Beyond the preview

Go deeper on Double homeobox 4 (DUX4) messenger RNA (DUX4 mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Double homeobox 4 (DUX4) messenger RNA (DUX4 mRNA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call